ストックスクリーナーアプリを入手
1.68
6.67%
-0.12
アフターアワーズ：
1.59
-0.09
-5.36%
前日終値:
$1.80
開ける：
$1.81
24時間の取引高:
109.56K
Relative Volume:
2.16
時価総額：
$8.93M
収益：
-
当期純損益:
$-16.63M
株価収益率:
-2.8475
EPS:
-0.59
ネットキャッシュフロー:
$-21.84M
1週間 パフォーマンス:
-15.15%
1か月 パフォーマンス:
-27.90%
6か月 パフォーマンス:
-70.53%
1年 パフォーマンス:
-34.50%
1日の値動き範囲:
$1.585
$1.86
1週間の範囲:
$1.585
$2.00
52週間の値動き範囲:
$1.585
$11.89
Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile
名前
Brainstorm Cell Therapeutics Inc
セクター
電話
201-488-0460
住所
1325 AVENUE OF AMERICAS, NEW YORK, NY
Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-02-04 | アップグレード | Maxim Group | Hold → Buy |
| 2020-11-17 | ダウングレード | Maxim Group | Buy → Hold |
| 2016-12-19 | 繰り返されました | Maxim Group | Buy |
| 2015-12-22 | 繰り返されました | Maxim Group | Buy |
Brainstorm Cell Therapeutics Inc (BCLI) 最新ニュース
BrainStorm regains Nasdaq compliance with bid price rule By Investing.com - Investing.com South Africa
BrainStorm regains Nasdaq compliance with bid price rule - Investing.com India
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - StockTitan
Neuromuscular Disease Therapeutics Market Statistical - openPR
BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting - Nasdaq
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Update - MarketBeat
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Cross Above 200-Day Moving AverageShould You Sell? - MarketBeat
Amyotrophic Lateral Sclerosis (ALS) Market: Detailed Analysis - openPR
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmBCLI - AsiaOne
Stem Cell Therapy Market Projected to Reach $831.9 Million By 2032 - 대구포스트
Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Declines By 91.1% - MarketBeat
Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Report By Type, Application and Geography - Elektrotransports.lv
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com - MarketBeat
BCLIBrainstorm Cell Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit - StockTitan
Gene and Cell Therapies for CNS Disorders Market to Experience - openPR
Brainstorm cell therapeutics CEO acquires $11,308 in stock By Investing.com - Investing.com Canada
Brainstorm cell therapeutics CEO acquires $11,308 in stock - Investing.com
Brainstorm Therapeutics Advances NurOwn® Phase 3b Trials - TipRanks
Brainstorm Cell Therapeutics, Inc. (BCLI) requires closer examination - US Post News
5 Best Stem Cell Companies to Invest In (November 2024) - Securities.io
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Research Coverage Started at StockNews.com - Defense World
Market Momentum: Brainstorm Cell Therapeutics, Inc. (BCLI) Registers a -12.57 Decrease, Closing at 0.22 - The Dwinnex
Brainstorm Cell Therapeutics, Inc. (BCLI) Stock: A Year of Market Fluctuations - The InvestChronicle
The Potential Rise in the Price of Brainstorm Cell Therapeutics, Inc. (BCLI) following insiders activity - Knox Daily
Cell Therapy Technologies Market Size, Product Trends, Key Drivers, Share Analysis And Forecast To 2033 - WhaTech
Brainstorm Cell Therapeutics Stock Scheduled to Reverse Split on Tuesday, October 1st (NASDAQ:BCLI) - Defense World
Cell Theraputics Industry Analysis by Regions, Types and Application - Elektrotransports.lv
BrainStorm announces reverse stock split - Investing.com
Stem Cell Therapy Market Growth, Size, Research Report and Forecast (2024-2034) - 대구포스트
BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting - PR Newswire
Global Stem Cell Therapy Market Set to Reach $ 831.9 Million by 2032 with a 17.2% CAGR GrowthGlobal Stem Cell Therapy Market Set to Reach $ 831.9 Million by 2032 with a 17.2% CAGR Growth - 대구포스트
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.com - Defense World
Cell Theraputics Market 2024-2032 Analysis - Economica
Balance Sheet Insights: Brainstorm Cell Therapeutics, Inc. (BCLI)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
BCLI’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
SEC Form S-3 filed by Brainstorm Cell Therapeutics Inc. - Quantisnow
Brainstorm Cell Therapeutics expands stock incentive plans - Investing.com India
Brainstorm Cell Therapeutics expands stock incentive plans By Investing.com - Investing.com Canada
Brainstorm Cell Therapeutics Enacts Key Corporate Changes - TipRanks
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Receives New Coverage from Analysts at StockNews.com - Defense World
Global Stem Cell Therapy Market Technology, Dimension, Vertical, and Regional Insights 2024-2032 - 대구포스트
Gene and Cell Therapies Targeting CNS Disorders Market Growth - openPR
Zacks Small Cap Analysts Reduce Earnings Estimates for Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Defense World
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Announces Earnings Results, Hits Expectations - Defense World
Thinking about buying stock in Brainstorm Cell Therapeutics, Cle - GuruFocus.com
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q2 2024 Earnings Call Transcript - Insider Monkey
BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update - Longview News-Journal
Earnings call: Brainstorm Cell Therapeutics outlines Phase 3b trial plans By Investing.com - Investing.com Canada
Earnings call: Brainstorm Cell Therapeutics outlines Phase 3b trial plans - Investing.com
Brainstorm Cell Therapeutics Inc (BCLI) 財務データ
収益
当期純利益
現金流量
EPS
Brainstorm Cell Therapeutics Inc (BCLI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lebovits Chaim | President & CEO |
Sep 30 '24 |
Buy |
0.23 |
22,000 |
5,016 |
1,186,865 |
| Dagher Ibrahim B. | Chief Medical Officer |
Jul 19 '24 |
Sale |
0.35 |
63,000 |
22,069 |
0 |
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):